CPT code 96401 describes the administration of non-hormonal anti-neoplastic chemotherapy or other highly complex drugs via subcutaneous or intramuscular injection. This procedure is distinguished from standard therapeutic injections (CPT 96372) by the inherent complexity of the agents involved, which often require specialized training for handling, preparation, and administration, as well as intensified patient monitoring for immediate toxicities or hypersensitivity reactions. These medications are typically hazardous materials that necessitate strict adherence to safety protocols, including the use of personal protective equipment (PPE) and specific disposal techniques for biohazardous and chemotherapeutic waste. The clinical process begins with a comprehensive review of the patient's medical record, including current laboratory values such as complete blood counts and metabolic panels to ensure the patient can safely receive the treatment. The clinician must verify the medication against the physician's order, ensuring the correct dosage is prepared, often involving double-verification by two licensed healthcare professionals. The injection site is selected based on the specific medication's pharmacokinetics and patient comfort, then prepared with an antiseptic agent. Following the administration of the drug, the patient is monitored for a period for signs of anaphylaxis or other adverse events. Documentation of the procedure must include the drug name, dosage, route of administration, the specific site of the injection, and the patient's tolerance. It is important to note that while 96401 is used for non-hormonal anti-neoplastics, its use also extends to certain monoclonal antibodies and biological response modifiers that carry similar levels of risk and complexity as traditional chemotherapy. Proper reporting requires understanding the distinction between hormonal and non-hormonal agents, as well as the unique risks associated with biologics.